PATH vs ZBH · P/E 19, rev $1.61B vs P/E 23, rev $7.68B
Uipath Inc (PATH) versus Zimmer Biomet Holdings Inc (ZBH) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Zimmer Biomet Holdings Inc (ZBH) is a medical devices company listed on NYSE.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported ZBH revenue for 2024-12-31 was $7.68B. Net income was $905.3M. Revenue was up 3.8% from 2023-12-31 to 2024-12-31. ZBH currently screens at market cap $17.13B and trailing P/E 22.9.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. ZBH currently screens at market cap $17.13B and trailing P/E 22.9.
Not investment advice. Open the PATH and ZBH stock pages for the full models.
Not investment advice.